Transcode Therapeutics (RNAZ) Cash & Equivalents (2020 - 2026)

Transcode Therapeutics (RNAZ) has 7 years of Cash & Equivalents data on file, last reported at $12.8 million in Q1 2026.

• Quarterly Cash & Equivalents rose 10.34% year-over-year to $12.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.8 million (up 10.34% YoY) and the FY2025 annual result came in at $17.8 million, up 206.54% from the prior year.
• Cash & Equivalents eased to $12.8 million in Q1 2026, from $17.8 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $17.8 million in Q4 2025 to a low of $1.6 million in Q1 2023.
• A 5-year average of $7.5 million and a median of $5.8 million in 2024 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2022 — Cash & Equivalents surged 16789.4% — and 2023, when it sank 90.51%.
• Tracing RNAZ's Cash & Equivalents over 5 years: stood at $5.0 million in 2022, then sank by 44.3% to $2.8 million in 2023, then jumped by 109.97% to $5.8 million in 2024, then jumped by 206.54% to $17.8 million in 2025, then decreased by 28.14% to $12.8 million in 2026.
• The last three Cash & Equivalents figures came in at $12.8 million (Q1 2026), $17.8 million (Q4 2025), and $2.8 million (Q3 2025), per Business Quant data.